FeesSafety
Pluang+

AvePoint appoints Ali Rohani as Chief Strategy and Customer Officer to boost AI trust and customer value.

Market News
04 Nov 2026, 16:00 WIB
GlobeNewsWire
View Source
Bullish
AvePoint appoints Ali Rohani as Chief Strategy and Customer Officer to boost AI trust and customer value.

AvePoint has named Ali Rohani as its new Chief Strategy and Customer Officer to lead global strategy and enhance customer value in the AI Trust market. Rohani brings over 25 years of experience from Qualtrics, Microsoft, and IBM, focusing on aligning customer needs with market strategy. His role will strengthen customer experience from onboarding to growth and help define AvePoint's AI Trust category. This appointment comes as AvePoint gains momentum with its new Trust Platform and recognition in Gartner's Magic Quadrant for AI Agent Management Platforms.

AvePoint's appointment of Ali Rohani as Chief Strategy and Customer Officer provides context for readers. For those tracking the Technology sector on Pluang as of Nov 04, 2026 20:01 WIB: out of 150 stocks, 77 rose and 66 fell. Notably, VNET rose 6.71% to USD 3.18 with a typical hold time of 18 days, while CORZ dropped 6.60% to USD 13.30 despite 100% buy order activity and a 23-day hold time. FIRY increased 6.33% to USD 13.28 but saw 100% sell order activity and a 14-day hold time.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App